Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys

Affiliation

• ¹ Pascale Palassin, PharmD, PhD, and Jean-Luc Faillie, MD, PhD, Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France; Cyrille Coustal, MD, Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-immune Diseases, Montpellier University Hospital, Montpellier, France; Xavier Quantin, MD, PhD, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France; Delphine Topart, MD, Department of Oncology, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France; François Roubille, MD, PhD, Department of Cardiology, Montpellier University Hospital, Montpellier, France; and Alexandre T.J. Maria, MD, PhD, Internal Medicine & Immuno-Oncology (MedIO), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.